p53MVA
AXP000187.1 · Cancer vaccine
- Platform
- MVA
- Targets
- TP53
- Sponsor
- City of Hope
Names
Virus
- Role
- Vaccine vector
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- MVA
- Replication
- non replicating
- Modifications
- wild-type TP53 cassette inserted into MVA
- Transgenes
- TP53
- Source
- evidence
Cross-references
- NCI Thesaurus
- C116868
Approvals
No regulatory approval recorded.
Clinical trials (4)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT03113487 | P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active not recruiting | Phase 2 | 2019-05-01 | 2022-08-26 | 29 | Recurrent Platinum-Resistant Fallopian Tube Carcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma; Recurrent Platinum-Resistant Primary Peritoneal Carcinoma |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active not recruiting | Phase 1 | 2015-12-28 | 2017-12-04 | 11 | Adult Solid Neoplasm; Bladder Carcinoma; Colon Carcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Head and Neck Squamous Cell Carcinoma; Hepatocellular Carcinoma; Melanoma; Non-Small Cell Lung Carcinoma; Pancreatic Carcinoma; Progesterone Receptor Negative; Rectal Carcinoma; Renal Cell Carcinoma; Soft Tissue Sarcoma; TP53 Gene Mutation; Triple-Negative Breast Carcinoma; Unresectable Solid Neoplasm |
| NCT02275039 | p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer | Completed | Phase 1 | 2015-02-06 | 2018-04-23 | 12 | Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Carcinoma |
| NCT01191684 | Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer | Completed | Phase 1 | 2011-12-22 | 2013-08-19 | 12 | Recurrent Colon Cancer; Recurrent Gastric Cancer; Recurrent Pancreatic Cancer; Recurrent Rectal Cancer; Stage III Colon Cancer; Stage III Gastric Cancer; Stage III Pancreatic Cancer; Stage III Rectal Cancer; Stage IV Colon Cancer; Stage IV Gastric Cancer; Stage IV Pancreatic Cancer; Stage IV Rectal Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 30094792 | Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2019 | name in title: p53MVA |
| PMID 29301826 | p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2018 | name in abstract: p53MVA |
| PMID 24987057 | p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2014 | cited by trial NCT01191684 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38032111 | Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer. | Cancer research communications | 2023 | name in title: p53MVA |
| PMID 28049162 | Correction: p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2017 | name in title: p53MVA |
| PMID 29209571 | Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab. | Oncoimmunology | 2017 | name in title: p53MVA |
| PMID 25941580 | Overcoming immunosuppression to enhance a p53MVA vaccine. | Oncoimmunology | 2014 | name in title: p53MVA |
| PMID 20551836 | Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression. | Journal of immunotherapy (Hagerstown, Md. : 1997) | 2010 | name in abstract: p53MVA |
Notes
MVA encoding wild-type human p53 (TP53); phase 1 trials at City of Hope, including with gemcitabine in recurrent ovarian cancer (NCT02275039, taken from trial listings, registry record not opened) and in refractory gastrointestinal cancers. Route not recorded here.
How to cite
p53MVA (AXP000187.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000187.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.